CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS INDEX Page Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Loss fo

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE LOSS FOR THE SIX MONTHS ENDED JUNE 30, 2022

accompanying notes are an integral part of these consolidated financial statements.

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITIONS

accompanying notes are an integral part of these consolidated financial statements.

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

THE SIX MONTHS ENDED JUNE 30, 2022 AND 2023

accompanying notes are an integral part of these consolidated financial statements.

THERAPEUTICS LIMITED AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

SIX MONTHS ENDED JUNE 30, 2022 AND 2023

accompanying notes are an integral part of these consolidated financial statements

THERAPEUTICS LIMITED AND SUBSIDIARIES

to the Unaudited Interim Condensed Consolidated Financial Statements

1 General Information

unaudited condensed financial statements are the interim financial statements of CytoMed Therapeutics Limited (the "Company")

and its subsidiaries (the "Group"), for the six months ended June 30, 2023 (the "Financial Statements").

Therapeutics Limited was incorporated in the Republic of Singapore on March 9, 2018. The Company is a public limited company incorporated

and domiciled in Singapore with registered office situated at 1 Commonwealth Lane, #08-22, Singapore 149544. The Company is headquartered

in Singapore and conducts its operations domestically and in Malaysia. The Company is listed on the Nasdaq Stock Exchange under the ticker

symbol "GDTC" on April 14, 2023.

immediate and ultimate holding corporation is Glorious Finance Limited, incorporated in the British Virgin Islands.

The principal activities of the Company

are to carry on the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research

and development of immune cell and stem cell-based therapy. The Company conducts its primary operations through its directly held wholly

owned subsidiary that is incorporated and domiciled in Malaysia, namely CytoMed Therapeutics (Malaysia) Sdn. Bhd., which is principally

engaged in manufacturing innate immune cell-based immunotherapy and pluripotent stem cell-based therapy and consultancy services and

undertaking the research and development of immune cell and stem cell-based therapy for advancing cellular immunotherapy to treat cancer.

The principal activities of

the subsidiaries of the Company are as follows:

2 Summary of significant accounting policies

Financial Statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") under the

historical cost convention, except as disclosed in the accounting policies below.

preparation of Financial Statements in conformity with IFRS requires management to exercise its judgement in the process of applying

the Group's accounting policies. It also requires the use of certain critical accounting estimates and assumptions. The areas involving

a higher degree of judgement or complexity, or areas where estimates and assumptions are significant to the Financial Statements.

The unaudited interim consolidated

financial statements do not include all the information and footnotes required by the IFRS for complete financial statements. Certain

information and note disclosures normally included in the annual financial statements prepared in accordance with the IFRS have been

condensed or omitted consistent with Article 10 of Regulation S-X. In the opinion of the Company's management, the unaudited interim

consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments,

in normal recurring nature, as necessary for the fair statements of the Company's financial positions as of June 30, 2023, and

results of operations and cash flows for the six-month period ended June 30, 2023. The unaudited interim condensed consolidated statements

of financial positions as of December 31, 2022 has been derived from the audited financial statements at that date but does not include

all the information and footnotes required by the IFRS. Interim results of operations are not necessarily indicative of the results expected

for the full fiscal year or for any future period. These financial statements should be read in conjunction with the audited consolidated

financial statements as of and for the years ended December 31, 2022, 2021 and 2020, and related notes included in the Company's

audited consolidated financial statements.

accounting policies adopted are consistent with those of the previous financial year except that in the current financial year, the Group

has adopted all the new and amended standards which are relevant to the Group and are effective for annual financial period beginning

on January 1, 2023. The adoption of these standards did not have any material effect on the financial statements of the Group.

All translations from Singapore

dollars to U.S. dollars and from U.S. dollars to Singapore dollars in this Report are made at a rate of S$1.3523 to U.S.$1.00, the exchange

rate in effect as of June 30, 2023 as set forth in the H.10 statistical release of the U.S. Board of Governors of the Federal Reserve

Prudent liquidity risk management

implies sufficient cash to finance the Group's and the Company's operations and development activities. The Group manages

the liquidity risk by maintaining a level of cash and cash equivalents deemed adequate to finance the Group's business operations

and development activities. The Group's objective is to maintain a balance between continuing of funding and flexibility through

the use of borrowings.

On April 18, 2023, the Company

completed its initial public offering. In this offering, the Company issued 2,412,369 ordinary shares at a price of U.S.$4.00 per share

for aggregate gross proceeds of S$12,938,017. As of June 30, 2023, the Group has negative cash flow from operating activities of S$2,033,700.

The Group's working capital was negative S$264,416 as of June 30, 2023. At the same time, the Group had S$10,437,795 in cash and

cash equivalents, which is unrestricted as to withdrawal and use as of June 30, 2023. In view of these circumstances, the management

of the Group has given consideration to the future liquidity and performance of the Group and its available sources of finance in assessing

whether the Group will have sufficient financial resources to continue as a going concern, at least, for the next twelve months from

the date of this report.

3 Significant accounting judgements and estimates

preparation of the Financial Statements requires management to make judgements, estimates and assumptions that affect the reported amounts

of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting period. However,

uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount

of the asset or liability affected in the future periods.

significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty

were the same as those that applied to the consolidated financial statements as at and for the year ended December 31, 2022.

4 Segment information

information by operating segment is not presented as the Group's operating segment relates solely on the business of innate immune

cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based

5 Other operating income

Group measures the convertible loans at fair value which was valued by the directors of the Company with reference to an independent

qualified professional valuer through profit or loss.

expenses include research personnel costs, depreciation of research equipment and consumables consumed for research activities.

8 Employee benefits expenses

benefits are recognized as an expense, unless the cost qualifies to be capitalized as an asset.